Nawrocka W, Zimecki M, Kuznicki T, Kowalska M W
Department of Technology of Drugs, Wroclaw University of Medicine, Poland.
Arch Pharm (Weinheim). 1999 Mar;332(3):85-90. doi: 10.1002/(sici)1521-4184(19993)332:3<85::aid-ardp85>3.0.co;2-s.
The reaction of 2-aminobenzimidazole with selected 4-methoxy-,2,4-dimethoxy-, 4-chloro-, 4-nitro-, and 2-nitrocinnamic acid under different conditions has been described. Two series of derivatives were obtained: 4-aryl-1,2,3,4-tetrahydropyrimido[1,2-a]-benzimidazol-2-ones (1-3) or substituted amides 4, 5, 7. The following compounds: 4-(p-methoxyphenyl)- (1), 4-(2,4-dimethoxyphenyl)- (2), 4-(p-chlorophenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazo l-2-one (3), amides: 2-(p-nitrocinnamoylamino)- (4), 2-(p-methoxycinnamoylamino)-benzimidazole (5), and 3-methyl-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-2-one (6), recently synthesized, have been selected for further studies. Among the studied compounds, 3 and 4 strongly inhibited PHA-induced proliferation of human lymphocytes and weaker, but significantly, MLC-induced lymphocyte proliferation. 3 and 4 inhibited also LPS- or MLC-induced TNF-alpha production. In addition, TNF-alpha production, induced by LPS, was inhibited by compounds 1 and 2. Higher activity of 3 and 4 could be associated with the presence in their structures of -Cl and -NO2 substituents as compared with compounds possessing -OCH3 groups. Compounds 3 and 4 were not toxic when administered orally to mice which predisposes them for further investigations with a chance of clinical application.
描述了2-氨基苯并咪唑与选定的4-甲氧基、2,4-二甲氧基、4-氯、4-硝基和2-硝基肉桂酸在不同条件下的反应。得到了两个系列的衍生物:4-芳基-1,2,3,4-四氢嘧啶并[1,2-a]苯并咪唑-2-酮(1-3)或取代酰胺4、5、7。以下化合物:4-(对甲氧基苯基)-(1)、4-(2,4-二甲氧基苯基)-(2)、4-(对氯苯基)-1,2,3,4-四氢嘧啶并[1,2-a]苯并咪唑-2-酮(3)、酰胺:2-(对硝基肉桂酰氨基)-(4)、2-(对甲氧基肉桂酰氨基)苯并咪唑(5)和3-甲基-1,2,3,4-四氢嘧啶并[1,2-a]苯并咪唑-2-酮(6),最近合成的,已被选作进一步研究。在所研究的化合物中,3和4强烈抑制PHA诱导的人淋巴细胞增殖,对MLC诱导的淋巴细胞增殖抑制作用较弱但显著。3和4也抑制LPS或MLC诱导的TNF-α产生。此外,LPS诱导的TNF-α产生被化合物1和2抑制。与具有-OCH3基团的化合物相比,3和4的较高活性可能与其结构中-Cl和-NO2取代基的存在有关。化合物3和4口服给予小鼠时无毒,这使其有机会进行进一步研究并有可能用于临床应用。